BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
0.4370
-0.0160 (-3.53%)
At close: Nov 19, 2026, 4:00 PM EST
0.4560
+0.0190 (4.35%)
After-hours: Nov 19, 2026, 7:30 PM EST
BeyondSpring Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
17.97M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.35M | - | - |
| Dec 31, 2021 | 1.35M | 1.17M | 650.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immutep | 13.79M |
| Evaxion | 7.49M |
| Metagenomi Therapeutics | 7.09M |
| ABVC BioPharma | 797.92K |
| CervoMed | 8.73K |
BYSI News
- 6 days ago - BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 days ago - BeyondSpring Earnings release: Q3 2026 - Filings
- 6 days ago - BeyondSpring Quarterly report: Q3 2026 - Filings
- 6 days ago - BeyondSpring Slides: Corporate presentation - Filings
- 24 days ago - BeyondSpring Slides: Corporate presentation - Filings
- 7 weeks ago - BeyondSpring Transcript: FDA announcement - Transcripts
- 7 weeks ago - BeyondSpring Press release: FDA announcement - Filings
- 7 weeks ago - BeyondSpring announces U.S. FDA granted Fast Track designation to Plinabulin - TheFly